TG Therapeutics (TGTX) Projected to Post Earnings on Monday

TG Therapeutics (NASDAQ:TGTX) is anticipated to announce its Q3 2026 results before the market opens on Monday, November 2nd. Analysts expect TG Therapeutics to announce earnings of $0.3668 per share and revenue of $245.47 million for the quarter. Parties can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Monday, November 2, 2026 at 8:30 AM ET.

TG Therapeutics (NASDAQ:TGTX) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.31 by ($0.26). TG Therapeutics had a return on equity of 73.49% and a net margin of 55.22%. The company had revenue of $240.34 million for the quarter, compared to analyst estimates of $229.77 million. During the same period in the prior year, the company earned $0.17 EPS. The company’s quarterly revenue was up 70.2% compared to the same quarter last year. On average, analysts expect TG Therapeutics to post $0.92 EPS for the current fiscal year and $2.65 EPS for the next fiscal year.

TG Therapeutics Price Performance

TG Therapeutics stock opened at $61.18 on Friday. The firm has a market cap of $9.36 billion, a PE ratio of 22.33, a price-to-earnings-growth ratio of 2.45 and a beta of 1.80. The company has a debt-to-equity ratio of 1.23, a current ratio of 4.27 and a quick ratio of 3.72. The stock’s fifty day moving average price is $55.33 and its two-hundred day moving average price is $43.75. TG Therapeutics has a one year low of $26.76 and a one year high of $61.76.

Analyst Upgrades and Downgrades

TGTX has been the topic of several analyst reports. Weiss Ratings lowered TG Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, October 23rd. Zacks Research raised TG Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 6th. JPMorgan Chase & Co. boosted their price target on TG Therapeutics from $65.00 to $72.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. Bank of America upped their price objective on shares of TG Therapeutics from $17.00 to $20.00 and gave the stock an “underperform” rating in a research report on Tuesday, July 7th. Finally, HC Wainwright reiterated a “buy” rating and set a $78.00 price objective on shares of TG Therapeutics in a research note on Tuesday, September 1st. Six analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $63.00.

Insider Buying and Selling

In other TG Therapeutics news, Director Laurence Charney sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $54.96, for a total transaction of $274,800.00. Following the completion of the transaction, the director directly owned 168,640 shares in the company, valued at $9,268,454.40. The trade was a 2.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 8.87% of the stock is currently owned by corporate insiders.

TG Therapeutics Company Profile

TG Therapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering medicines for B-cell diseases, including multiple sclerosis and certain blood cancers. The company’s research and development programs are centered on therapies that target B cells and the immune system.

TG Therapeutics’ primary marketed product is BRIUMVI (ublituximab-xiiy), an anti-CD20 monoclonal antibody approved in the United States for the treatment of relapsing forms of multiple sclerosis in adults.